BIOSYNTIA APS

Their core work

Biosyntia is a Danish biotech SME specializing in microbial cell factory engineering — designing and optimizing microorganisms to produce valuable chemicals and compounds through fermentation. Their H2020 work spans metabolic engineering, bioinformatics-driven cell design, and synthetic biology tools for industrial bioprocesses. They contribute applied expertise in building and refining microbial production strains, bridging the gap between computational design of metabolic pathways and their real-world implementation in biomanufacturing.

What they specialise in

How they've shifted over time

Biosyntia's early H2020 involvement (2015-2016) focused on foundational analytical and computational tools — single-cell metabolite analysis (MetaRNA) and bioinformatics platforms for designing cell factories (DD-DeCaF). Their later projects (2017-2018) shifted toward applied synthetic biology for industrial production, including engineering bacterial membrane structures (Rafts4Biotech) and building robust synthetic genetic circuits (SynCrop). The trajectory shows a clear move from measurement and modeling toward hands-on bioprocess engineering and production optimization.

Biosyntia is moving toward applied synthetic biology tools that make microbial production more reliable and scalable, making them a strong partner for projects translating lab-stage bioprocesses into industrial manufacturing.

How they like to work

Biosyntia participates exclusively as a partner rather than a coordinator, positioning themselves as an industry-side specialist within larger research consortia. With 43 unique partners across 13 countries from just 4 projects, they operate in broad, multi-national consortia — typical of Marie Skłodowska-Curie training networks and large RIA projects. This suggests they are valued for their applied industrial perspective and are comfortable integrating into academic-led teams as the biotech implementation partner.

Biosyntia has built a diverse European network of 43 partners across 13 countries through just 4 projects, reflecting participation in large training networks and research consortia. Their connections span academic research groups and industrial biotech partners primarily in Western and Northern Europe.

What sets them apart

Biosyntia brings a rare combination: they are a commercial biotech SME with deep roots in both computational metabolic design and hands-on fermentation engineering. Where most academic partners stop at modeling, Biosyntia carries the work toward actual microbial production strains. For consortium builders, they fill the critical gap between university-stage pathway design and industrial-scale biomanufacturing — an SME that can both speak the language of systems biology and deliver production-ready organisms.

Highlights from their portfolio

• Rafts4Biotech
  Largest EC contribution (EUR 555,250) and most technically distinctive — engineering synthetic lipid rafts in bacteria to compartmentalize and optimize industrial enzymatic processes.
• DD-DeCaF
  Directly aligned with Biosyntia's core business of computational cell factory design, developing open bioinformatics services for data-driven metabolic engineering.